세계의 악성 복수 시장 : 시장 인사이트, 역학, 시장 예측(-2034년)

Malignant Ascites - Market Insights, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,518,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,278,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,037,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 34,556,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

악성 복수(MA)는 다양한 복부 및 복부 외부의 원발성 신 생물 별 병태입니다. 이환율의 주요 원인이며 많은 어려움과 치료 과제를 초래합니다. 악성 복수는 복강 내에 악성 세포가 존재하는 복막 암종증의 징후입니다. 악성 복수는 암별 복강 내에 액체가 비정상적으로 저장되는 것을 특징으로 하며 몇 가지 명확한 증상을 나타냅니다. 하나의 주요 지표는 뚜렷한 복부의 부종 또는 팽창이며, 종종 복부 증가로 이어집니다. 악성 복수의 병태 생리학은 다 요인입니다. 종양 혈관의 투과성이 항진하고 복막액이 강제적으로 생산 및 방출되는 것이 악성 복수 발생의 주요 요인입니다.

복강 내 액 생산의 원인은 간경변, 울혈성 심부전, 네프로제, 췌장염, 복막염, 원발성 악성 종양, 간 전이 등 다양합니다. 양성 복수와 악성 복수의 감별은 신체 진찰이나 X선 검사만으로는 불가능합니다. 양자의 감별에는 침습적 검사가 필요합니다.

2020년 주요 7개국에서 악성 복수 시장 규모는 19억 9,000만 달러에 달했습니다. 이 시장은 2034년에는 23억 4,000만 달러로 증가할 것으로 예측됩니다. 미국의 악성 복수 시장 규모는 2020년에 약 8억 달러가 되었지만, 2034년에는 11억 4,500만 달러로 확대될 것으로 예측됩니다. 2034년까지 모든 치료법 중 가장 수익이 예상되는 것은 화학요법(6억 5,000만 달러)이며, 가장 수익이 예상되지 않는 것은 이뇨제 병용 요법(2억 4,000만 달러) 입니다.

EU 4개국과 영국에서 악성 복수 시장 규모는 2020년에 약 4억 9,000만 달러가 되었지만, 2034년에는 5억 4,000만 달러로 증가할 것으로 예측됩니다. 일본의 악성 복수 시장 규모는 2020년 6억 9,000만 달러였지만, 2034년에는 6억 5,000만 달러로 감소할 것으로 예측됩니다.

본 보고서는 주요 7개국의 악성 복수 시장에 대해 조사했으며,, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 의료의 미충족 요구 등을 제공합니다.

목차

제1장 중요한 인사이트

제2장 보고서의 소개

제3장 악성 복수의 주요 요약

제4장 악성 복수 시장 개요

제5장 주요 사건

제6장 악성 복수: 질환의 배경과 개요

• 소개
• 징후와 증상
• 병태생리학
• 진단
• 치료 관리

제7장 역학과 환자 인구

• 주요 조사 결과
• 전제와 근거
• 주요 7개국에 있어서의 악성 복수 관련 암의 발생 총수
• 주요 7개국에 있어서의 악성 복수의 전체 환자 총수
• 미국
• EU 4개국과 영국
• 일본

제8장 환자 동향

제9장 가미시 끝난 약제

제10장 신흥 약제

제11장 악성 복수: 시장 분석

• 주요 조사 결과
• 시장 전망
• 주요 7개국에 있어서의 악성 복수의 총 시장 규모
• 미국 시장 규모
• 일본 시장 규모

제12장 언멧 요구

제13장 SWOT 분석

제14장 KOL의 견해

제15장 시장 접근과 상환

• 미국
• EU 4개국과 영국
• 일본

제16장 부록

제17장 DELVEINSIGHT의 기능

제18장 면책사항

제19장 DELVEINSIGHT 정보

BJH

영문 목차

영문목차

Key Highlights:

• Malignant ascites (MA) is a pathological condition due to a variety of primary abdominal and extra-abdominal neoplasms. It is a primary cause of morbidity and presents many difficulties and treatment challenges. Malignant ascite is a sign of peritoneal carcinomatosis, the presence of malignant cells in the peritoneal cavity.
• Malignant ascites, characterized by the abnormal accumulation of fluid in the abdominal cavity due to cancer, present with several distinct symptoms. One primary indicator is noticeable abdominal swelling or distension, often leading to an increase in girth.
• The pathophysiology of Malignant ascites is multifactorial. Increased permeability of tumor vessels, with forced production and release of peritoneal fluid, is the main factor in Malignant ascites development.
• The causes of intra-abdominal fluid production are many, including cirrhosis, congestive heart failure, nephrosis, pancreatitis, peritonitis, primary malignancy, or hepatic metastases. It is not possible to distinguish benign ascites from malignant ascites by physical exam or radiographic techniques alone. Invasive testing is necessary to differentiate the two types.
• (Baretti et al., 2019) conducted a study in Japan and reported the prevalence of ascites in patients with gastrointestinal cancers is 21% typically from malignancies such as pancreatic, gastric, colorectal, and gallbladder cancers.
• In 2020, the total incident cases of Malignant Ascites associated cancers were ~ 1.6 million in the 7MM.
• Many treatments are palliative, focusing on symptom relief and improving the quality of life rather than providing a cure for malignant ascites. With only two approved therapies, i.e., OK-432 and KM-CART in Japan, most patients are limited to the best palliative care, which is often inadequate to address these unmet needs.
• In 2020, in the 7MM the total market size of Malignant ascites was ~ USD 1990 million.

DelveInsight's " Malignant ascites - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Malignant ascites, historical and forecasted epidemiology as well as the Malignant ascites market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Malignant ascites market report provides current treatment practices, emerging drugs, Malignant ascites market share of the individual therapies, and current and forecasted Malignant ascites market size from 2020 to 2034, segmented by seven major markets. The report also covers current Malignant ascites treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Malignant ascites Disease Understanding and Treatment Algorithm

Malignant ascites Overview

Malignant ascites (MA) is a pathological condition due to a variety of primary abdominal and extra-abdominal neoplasms. It is a primary cause of morbidity and presents many difficulties and treatment challenges. Malignant ascite is a sign of peritoneal carcinomatosis, the presence of malignant cells in the peritoneal cavity. Tumors causing carcinomatosis are more commonly secondary peritoneal surface malignancies, which include ovarian, colorectal, pancreatic, and uterine; extra-abdominal tumors originating from lymphoma, lung, and breast; and a small number of unknown primary tumors.

Malignant ascites Diagnosis

The causes of intra-abdominal fluid production are many, including cirrhosis, congestive heart failure, nephrosis, pancreatitis, peritonitis, primary malignancy, or hepatic metastases. It is not possible to distinguish benign ascites from malignant ascites by physical exam or radiographic techniques alone. Invasive testing is necessary to differentiate the two types. Abdominal paracentesis with ascitic fluid analyses can diagnose malignant causes of ascite production in most cases, but laparoscopic tissue sampling may be necessary. Recently, several molecular profiling studies aimed at examining the different contents of MA, such as soluble molecules (proteins, DNA, and RNA), extracellular vesicles (EVs), and cells, have provided new insights into the outcome of PDAC (pancreatic ductal adenocarcinoma) patients with MA.

Further details related to diagnosis will be provided in the report...

Malignant ascites Treatment

With only two approved therapies, i.e., OK-432 and KM-CART in Japan, most patients are limited to the best palliative care, which is often inadequate to address these unmet needs. Several treatment modalities can alleviate the symptoms associated with malignant ascites. Because the natural history of ascite formation is poorly understood, these measures and quality of life data are limited, and the efficacy of existing treatments is difficult to assess. Traditional modalities for managing malignant ascites include sodium-restricted diets, diuretic therapy, serial paracentesis, and peritoneovenous shunting.

Further details related to treatment will be provided in the report.....

Malignant ascites Epidemiology

The Malignant ascites epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incident cases of Malignant ascites associated cancers, total patient pool of malignant ascites in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Among the 7MM, the United States accounted for the highest incident cases of Malignant ascites in 2020, with around 350,000 cases; these cases are expected to increase during the forecast period.
• Among all the associated cancers, the highest incident cases were reported in Breast Cancer. In 2020 the total incident cases of Breast Cancer were 640,000.
• In 2020, the total patient pool of Malignant Ascites were 390,000 in the EU4 and the UK.

Malignant ascites Drug Chapters

The drug chapter segment of the Malignant ascites report encloses a detailed analysis of the early-stage (Phase I/II and Phase I), mid-stage (Phase II and Phase II/III), and late-stage (Phase III) pipeline drug. The current key players for emerging drugs and their respective drug candidates include Lindis Biotech (Catumaxomab), Wuhan YZY Biopharma (M701). The drug chapter also helps understand the Malignant ascites clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

Emerging Drugs

Catumaxomab: Lindis Biotech

Catumaxomab is a bispecific trifunctional antibody that binds directly to the tumor cell with one of its binding sites. It activates two essential components of the immune system with the other binding sites: T cells and macrophages (scavenger cells). The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells. The EpCAM marker is present on almost all carcinomas and is, therefore, a promising approach for targeted cancer treatment. As per company pipeline, catumaxomab is in the preregistration stage of development for the treatment of Malignant ascites.

M 701: Wuhan YZY Biopharma

M701 is a new biological Class I drug that targets both EpCAM and CD3 being developed by YBODY Biotech through its independently patented asymmetric bispecific antibody YBODY(R) platform. The drug is mainly used for the treatment of malignant ascites (MA) and malignant pleural effusion (MPE) derived from EpCAM-positive cancer.M701 dual-antibody targets the EpCAM antigen on one end. At the same time, the CD3 antibody on the other end can bridge T cells and activate T cells to kill EpCAM-positive tumor cells. Currently, M701 is in the Phase II stage of development for the treatment of malignant ascites.

Drug Class Insight

Antibody-dependent cell cytotoxicity

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a crucial mechanism of the immune system involving the targeting and destruction of pathogenic cells by effector cells, particularly natural killer (NK) cells. ADCC is a process where specific antibodies bind to pathogens, marking them for destruction by NK cells through the injection of cytotoxic factors, leading to cell lysis. Antibodies recognize and bind to target cells, which are then attacked and destroyed by effector cells like NK cells. This process plays a vital role in immune responses against pathogens and cancer cells.

Malignant ascites Market Outlook

With only two approved therapies, i.e., OK-432 and KM-CART in Japan, most patients are limited to the best palliative care, which is often inadequate to address these unmet needs.. Only few key players are active in the pipeline such as Lindis Biotech and Wuhan YZY Biopharma for the treatment of Malignant ascites.

OK-432 (Picibanil) is a freeze-dried biological product that is prepared from the Su strain of Streptococcus pyogenes (group A) by treatment with benzylpenicillin and heat. OK-432 has been reported to induce various cytokines, activate immunological cells, and thus augment anticancer immunity.

KM-CART is a novel cell-free and concentrated ascites reinfusion therapy. It is modified from a conventional CART approved by the Ministry of Health, Labor and Welfare in Japan. KM-CART is easier to use and can be applied for massive malignant ascites.

Detailed market assessment will be provided in the final report.

Key Findings

• The total market size of Malignant Ascites in the 7MM was approximately USD 1,990 million in 2020, which is anticipated to rise to USD 2,340 million by 2034.
• The total market size of Malignant Ascites in the United States was approximately USD 800 million in 2020, which is anticipated to rise to USD 1,145 million by 2034.
• By 2034, among all the therapies, the highest revenue is expected to be generated by chemotherapy i.e., USD 650 million, while the lowest revenue is expected to be generated by Concomitant diuretic therapy, i.e., USD 240 million in the US.
• The total market size of Malignant Ascites in the EU4 and the UK was approximately USD 490 million in 2020, which is anticipated to rise to USD 540 million by 2034.
• The total market size of Malignant Ascites in Japan was USD 690 million in 2020, which is anticipated to decline to USD 650 million by 2034.

Malignant ascites Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034. The landscape of Malignant ascites treatment has experienced a transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncologists and the entire healthcare community in their tireless pursuit of advancing care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Malignant ascites Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III, Phase II and Phase I. It also analyzes key players involved in developing targeted therapeutics. Companies like Lindis Biotech and Wuhan YZY Biopharma actively engage in late stage research and development efforts for Malignant ascites. The pipeline of Malignant ascites possesses few potential drugs. However, there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2024-2034).

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Malignant ascites emerging therapy.

Market Access and Reimbursement

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), third-party organizations that provide services and educational programs to aid patients are also present.

A zero-dollar copay program is a healthcare initiative designed to eliminate out-of-pocket costs for patients when obtaining specific medical services or prescription medications. Under this program, individuals enrolled in health insurance plans or prescription drug benefit programs can access certain services or medications without having to make any direct financial contributions in the form of copayments. The program is often implemented to improve medication adherence and access to essential healthcare services, particularly for chronic conditions. Pharmaceutical manufacturers or healthcare providers may offer zero-dollar copay programs as a strategy to make necessary treatments more affordable and accessible for patients, ultimately enhancing overall health outcomes and patient satisfaction.

Detailed market access and reimbursement assessment will be provided in the final report.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of Malignant ascites, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of mid-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Malignant ascites market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive Malignant ascites.

Malignant ascites Report Insights

• Patient Population
• Therapeutic Approaches
• Malignant ascites Pipeline Analysis
• Malignant ascites Market Size and Trends
• Existing and Future Market Opportunity

Malignant ascites Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Malignant ascites Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Malignant ascites Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

FAQs

• What was the Malignant ascites market size, the market size by therapies, market share (%) distribution in 2023, and what would it look like by 2034? What are the contributing factors for this growth?
• What can be the future treatment paradigm for Malignant ascites?
• What are the disease risks, burdens, and unmet needs of Malignant ascites? What will be the growth opportunities across the 7MM concerning the patient population with Malignant ascites?
• What are the current options for the treatment of Malignant ascites? What are the current guidelines for treating Malignant ascites in the 7MM?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?
• What is the patient share in Malignant ascites?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving Malignant ascites.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis ranking of class-wise potential current and emerging therapies under the analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY OF MALIGNANT ASCITES

4. MALIGNANT ASCITES MARKET OVERVIEW AT A GLANCE

• 4.1. MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF MALIGNANT ASCITES IN 2020 IN THE 7MM
• 4.2. MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF MALIGNANT ASCITES IN 2034 IN THE 7MM

5. KEY EVENTS

6. MALIGNANT ASCITES: DISEASE BACKGROUND AND OVERVIEW

• 6.1. INTRODUCTION
• 6.2. SIGN AND SYMPTOMS
• 6.3. PATHOPHYSIOLOGY
  • 6.3.1. Peritoneal Physiology
  • 6.3.2. Pathophysiology of Malignant Ascites
• 6.4. DIAGNOSIS
• 6.5. TREATMENT MANAGEMENT
  • 6.5.1. Paracentesis
  • 6.5.2. Peritoneovenous Shunts
  • 6.5.3. Diuretics
  • 6.5.4. Drainage Catheters

7. EPIDEMIOLOGY AND PATIENT POPULATION

• 7.1. KEY FINDINGS
• 7.2. ASSUMPTIONS AND RATIONALE
• 7.3. TOTAL INCIDENT CASES OF MALIGNANT ASCITES ASSOCIATED CANCERS IN THE 7MM
• 7.4. TOTAL PATIENT POOL OF MALIGNANT ASCITES IN THE 7MM
• 7.5. THE UNITED STATES
  • 7.5.1. Total Incident Cases of Malignant Ascites Associated Cancers in the US
  • 7.5.2. Total Patient Pool of Malignant Ascites in the US
• 7.6. EU4 AND THE UK
  • 7.6.1. Total Incident Cases of Malignant Ascites Associated Cancers in EU4 and the UK
  • 7.6.2. Total Patient Pool of Malignant Ascites in EU4 and the UK
• 7.7. JAPAN
  • 7.7.1. Total Incident Cases of Malignant Ascites Associated Cancers in Japan
  • 7.7.2. Total Patient Pool of Malignant Ascites in Japan

8. PATIENT JOURNEY

9. MARKETED DRUGS

• 9.1. OK-432: ROCHE
  • 9.1.1. Product Description
  • 9.1.2. Regulatory Milestones
  • 9.1.3. Others Developmental Activities
  • 9.1.4. Safety and Efficacy
  • 9.1.5. Product Profile
• 9.2. KM-CART: ASAHI KASEI MEDICAL CO. LTD.
  • 9.2.1. Product Description
  • 9.2.2. Regulatory Milestones
  • 9.2.3. Safety and Efficacy
  • 9.2.4. Product Profile

10. EMERGING DRUGS

• 10.1. KEY COMPETITORS
• 10.2. CATUMAXOMAB: LINDIS BIOTECH
  • 10.2.1. Product Description
  • 10.2.2. Other Developmental Activities
  • 10.2.3. Clinical Development
    • 10.2.3.1. Clinical Trials Information
  • 10.2.4. Safety and Efficacy
• 10.3. M 701: WUHAN YZY BIOPHARMA CO., LTD.
  • 10.3.1. Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3. Clinical Development
    • 10.3.3.1. Clinical Trials Information
  • 10.3.4. Safety and Efficacy
• 10.4. SCB-313: CLOVER BIOPHARMACEUTICALS
  • 10.4.1. Product Description
  • 10.4.2. Other Developmental Activities
  • 10.4.3. Clinical Development
    • 10.4.3.1. Clinical Trials Information
  • 10.4.4. Safety and Efficacy
• 10.5. VAK: BINHUI BIOPHARMACEUTICAL
  • 10.5.1. Product Description
  • 10.5.2. Clinical Development
    • 10.5.2.1. Clinical Trials Information
• 10.6. CYPSCAPS PLUS IFOSFAMIDE: PHARMACYTE BIOTECH INC.
  • 10.6.1. Product Description
  • 10.6.2. Other Developmental Activities
  • 10.6.3. Safety and Efficacy

11. MALIGNANT ASCITES: MARKET ANALYSIS

• 11.1. KEY FINDINGS
• 11.2. MARKET OUTLOOK
• 11.3. TOTAL MARKET SIZE OF MALIGNANT ASCITES IN THE 7MM
• 11.4. UNITED STATES MARKET SIZE
  • 11.4.1. Total Market Size of Malignant Ascites in the United States
  • 11.4.2. Market Size of Malignant Ascites by Therapies in the United States
• 11.5. EU4 AND THE UK MARKET SIZE
  • 11.5.1. Total Market Size of Malignant Ascites in EU4 and the UK
  • 11.5.2. Market Size of Malignant Ascites by Therapies in EU4 and the UK
• 11.6. JAPAN MARKET SIZE
  • 11.6.1. Total Market Size of Malignant Ascites in Japan
  • 11.6.2. Market Size of Malignant Ascites by Therapies in Japan

12. UNMET NEEDS

13. SWOT ANALYSIS

14. KOL VIEWS

15. MARKET ACCESS AND REIMBURSEMENT

• 15.1. UNITED STATES
  • 15.1.1. Center for Medicare & Medicaid Services (CMS)
  • 15.1.2. Zero Dollar Copay (ZDC)
• 15.2. EU4 AND THE UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. United Kingdom
• 15.3. JAPAN
  • 15.3.1. MHLW

16. APPENDIX

• 16.1. BIBLIOGRAPHY
• 16.2. REPORT METHODOLOGY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT